The Ohio Secretary of State certified yesterday 116,015 signatures of registered Ohio voters who support the Ohio Drug Price Relief Act, a proposed statewide ballot initiative that will revise Ohio law to require state programs pay the same or less for prescription medications as the U.S. Department of Veterans Affairs. Drug pricing advocates affil
ALEXANDRIA, Va., Dec. 31 Alexion Pharmaceuticals, Cheshire, Connecticut, has been assigned a patent developed by four co-inventors for "methods of treating complement-associated disorders with anti-C5a antibodies." The co-inventors are Russell P. Rother, Oklahoma City, Douglas L. Sheridan, Branford, Connecticut, Paul P. Tamburini, Kensington, Con
Release date- 28122015- Basilea Pharmaceutica Ltd. today provided an update on the planned clinical phase 3 development program for its antibiotic ceftobiprole in the United States and reported completion of patient recruitment and interim data from the ongoing phase 1/ 2 a study with the intravenous formulation of its oncology drug candidate BAL10
-Princeton, New Jersey and Lund, Sweden 30 December 2015 Braeburn. Pharmaceuticals and Camurus announce that the first patient has been randomized. in the double blind Phase 3 efficacy trial of CAM2038 in opioid-dependent.
By a News Reporter-Staff News Editor at Politics& Government Week Clovis Oncology, Inc. announced that the U.S. Food and Drug Administration has extended the Prescription Drug User Fee Act date for Clovis' New Drug Application for rociletinib by the standard extension period of three months with the new goal date of June 28, 2016. Clovis Oncology
The three patents have been previously invalidated for obviousness by the court in the Southern District of New York in Purdue Pharma, L.P.' s suit against Teva Pharmaceuticals USA, Inc. Purdue appealed the obviousness ruling to the Federal Circuit, which heard oral arguments on November 3, 2015. x0D;. Purdue's initiation of a patent infringement
Sheila Davalloo, 46, formerly of Pleasantville, New York, tried to prevent her husband from testifying at her trial in 2012, citing the marital communications privilege in state law. Raymundo was beaten and stabbed nearly 20 times in her Stamford condominium. The three worked together at Stamford- based pharmaceutical company Purdue Pharma.
ALEXANDRIA, Va., Dec. 31 Gilrose Pharmaceuticals, White Plains, New York, has been assigned a patent developed by two co-inventors for "pharmaceutical intervention and method for treating an apraxia of speech in children." The co-inventors are Bruce Roseman, White Plains, New York, and Gilla Kaplan, New York. Written by Amal Ahmed; edited by Jaya
Global Blood Therapeutics, Inc., a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, announced today that the U.S. Food and Drug Administration has granted orphan drug designation for GBT440 for the treatment of patients with sickle cell disease.
-Insys Therapeutics, Inc. today announced that Dan Brennan, Chief Operating Officer, and Darryl Baker, Chief Financial Officer, will present at the J.P. Morgan 34th Annual Healthcare Conference as follows:. About Insys Therapeutics, Inc.Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and no
NEW YORK, NY/ ACCESSWIRE/ December 31, 2015/ LifeSci Capital, LLC, a research-driven investment bank with deep domain expertise in the life sciences sector, today announced that it has initiated coverage of TetraLogic Pharmaceuticals, a clinical-stage biopharmaceutical company developing therapies for cancer and infectious diseases.
Dec. 30 MANATEE A Manatee County fire department has received a donation of a drug that will help in the fight against opioid overdose deaths. In July 2014, EVZIO became available in the U.S. by prescription and "is the first and only FDA- approved naloxone product specifically indicated for the emergency treatment of known or suspected opioid
The Report Proliferative Vitreoretinopathy Global Clinical Trials Review, H2, 2015 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants.Albany, NY 12/31/2015 MarketResearchReports.Biz presents this most up-to-date research on "Proliferative Vitreoretinopathy Global Clinical...
-NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system disorders, today announced the start of patient enrollment in a first efficacy trial of ND0612H, the companys continuously administered subcutaneous levodopa/carbidopa solution. This treatment is intended to be an alternative to current treatments..
-PharmaCyte Biotech, Inc., a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today a shareholder update on PharmaCytes pancreatic cancer and diabetes programs. Manuel Hidalgo, and experts at Translational Drug...
ALEXANDRIA, Va., Dec. 31 Purdue Pharma, Stamford, Connecticut, has been assigned a patent developed by two co-inventors for buprenorphine analogs. The co-inventors are Donald J. Kyle, Yardley, Pennsylvania, and Laykea Tafesse, Robbinsville, New Jersey. Written by Kusum Sangma; edited by Jaya Anand.
Researchers Submit Patent Application, "Method of Treating an Ocular Disease and Compositions Effective for Treating an Ocular Disease", for Approval. By a News Reporter-Staff News Editor at Women's Health Weekly From Washington, D.C., NewsRx journalists report that a patent application by the inventors Karla, Pradeep K.; Mangat, Harpal S., filed
By a News Reporter-Staff News Editor at Politics& Government Week From Washington, D.C., VerticalNews journalists report that a patent application by the inventors PITTET, Michel; VALLOTTON, Raphael; LAMPRECHT, Volker, filed on January 22, 2014, was made available online on December 17, 2015. No assignee for this patent application has been made.
By a News Reporter-Staff News Editor at Women's Health Weekly Roche announced that it has filed a direct de novo application to the U.S. Food and Drug Administration for a fully automated Anti-Mullerian assay for use on Roche's full portfolio of laboratory analyzers. Alan Wright, Chief Medical Officer, Roche Diagnostics Corporation. The assay is
Transparency Market Research Report Added "Women Health Therapeutics Market" to its database.Albany, NY 12/31/2015 The presence of several leading pharmaceutical companies in the development of women's health therapeutics is a key factor driving the global market, states Transparency Market Research in its latest report. The major drugs in th
Teligent, Inc., a New Jersey- based specialty generic pharmaceutical company, today announced it has submitted its fourteenth and fifteenth abbreviated new drug applications to the U.S. Food and Drug Administration of 2015, which brings the Company's total number of ANDA submissions now pending at the FDA to thirty-three. We believe our current p
Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, today announced that the U.S. Food and Drug Administration has granted the Company s PLX-PAD cells Orphan Drug Designation in the treatment of severe preeclampsia. Attainment of Orphan Drug Designation for our cells in severe preeclampsia exemplifies o
Immune Pharmaceuticals has announced it will exclusively license from Atlante Biotech the patents and know-how for a new format of bispecific antibodies. Immune CEO Daniel Teper, PharmD, said, "This is an important milestone as we make progress with our immuno-oncology pipeline. R&D work on the bispecific antibodies will be conducted at Immune's ne
ALPS, a DST Company focused on asset management and asset servicing, today announced the launch of the ALPS Medical Breakthroughs ETF, the first exchange-traded fund built specifically to capture R&D opportunities in the biotechnology and pharmaceutical industries. According to Michael Akins, Senior Vice President, Portfolio Manager for the ALPS ET
Release date- 30122014- New York, NY- Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system and various types of cancer, today reported fourth quarter and year-end results for fiscal year 2014.. Anavex had cash and cash equiv